GLP-1 demand is going to remain higher than supply for foreseeable future, says BMO's Evan Seigerman
Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's ...
Bristol-Myers Squibb: Hold Rating Amid New Schizophrenia Drug Launch and Patent Expiries
Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price ...
Pfizer’s Solid Fundamentals and Strategic Acquisitions Affirm Buy Rating Despite Oxbryta Setback
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report), retaining the price target of $36.00.
BioSpace7h
Pfizer’s Oxbryta Withdrawal Leaves Sickle Cell Community Scrambling, Investors Reeling
Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...
The best biotech plays outside the GLP-1 weight-loss market
BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination to discuss the best ...
BioPharma Dive7d
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...
BioSpace9d
Despite Win Over Keytruda, Summit’s NSCLC Bispecific Still Has Something to Prove
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
The Motley Fool11d
Is Pfizer Stock Going to $36? 1 Wall Street Analyst Thinks So.
BMO Capital's Evan David Seigerman recently reiterated his outperform (i.e., buy) recommendation on Pfizer. He also maintained his $36-per-share price target on the well-known healthcare stock ...